Xiongbin Lu

机构：Indiana University Health, The University of Texas MD Anderson Cancer Center, Indiana Cancer Consortium, Indiana University School of Medicine, Indiana University – Purdue University Indianapolis, Zhejiang University · ORCID：0000-0002-7987-9825

发表论文 190 篇 · 总被引 11008 次 · h-index 59

代表论文

• Elevated protein lactylation promotes immunosuppressive microenvironment and therapeutic resistance in pancreatic ductal adenocarcinoma (2025 · Journal of Clinical Investigation · 被引 110)
• In-situ cryo-immune engineering of tumor microenvironment with cold-responsive nanotechnology for cancer immunotherapy (2023 · Nature Communications · 被引 78)
• A T Cell‐Engaging Tumor Organoid Platform for Pancreatic Cancer Immunotherapy (2023 · Advanced Science · 被引 64)
• Lipid droplet-associated lncRNA LIPTER preserves cardiac lipid metabolism (2023 · Nature Cell Biology · 被引 63)
• Sphingolipid synthesis in tumor-associated macrophages confers immunotherapy resistance in hepatocellular carcinoma (2025 · Science Advances · 被引 32)
• A multidimensional platform of patient-derived tumors identifies drug susceptibilities for clinical lenvatinib resistance (2023 · Acta Pharmaceutica Sinica B · 被引 24)